Beta Bionics Chief Commercial Officer Hopman Mark sold 775 shares at $15.52 each on 2026-09-14, leaving an ownership position of 86,382 shares. The sale represented about 0.9% of his prior holding, allowing investors to distinguish the transaction from the larger position that remained afterward.

Key Highlights

  • The transaction took place on 14 September 2026 under SEC transaction code S.
  • Hopman Mark held 86,382 Beta Bionics shares after the sale.
  • The disposal represented about 0.9% of his prior shareholding.

Beta Bionics, Inc. (NASDAQ: BBNX) shares were sold by Chief Commercial Officer Hopman Mark in a transaction covering 775 shares at $15.52 each. The disposal represented about 0.9% of his prior holding. Hopman Mark is identified as Beta Bionics’ chief commercial officer. The transaction date was 14 September 2026. The record prices each transferred share at $15.52 and identifies the transaction as involving Beta Bionics shares.

Post-Transaction Holding Stood at 86,382 Shares

Mark held 86,382 Beta Bionics shares after completing the transaction. The reported 0.9% figure is measured against his prior shareholding, while the 86,382-share figure describes his position afterward. The two figures therefore refer to different points in the transaction timeline.